307 related articles for article (PubMed ID: 4045923)
21. Synthesis and receptor specificities of vasopressin antagonists.
Manning M; Sawyer WH
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S29-35. PubMed ID: 2434768
[TBL] [Abstract][Full Text] [Related]
22. [1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
Manning M; Lowbridge J; Stier CT; Haldar J; Sawyer WH
J Med Chem; 1977 Sep; 20(9):1228-30. PubMed ID: 926126
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of potent in vivo antagonists of oxytocin.
Bankowski K; Manning M; Seto J; Haldar J; Sawyer WH
Int J Pept Protein Res; 1980 Nov; 16(5):382-91. PubMed ID: 7216614
[TBL] [Abstract][Full Text] [Related]
24. N-Acetyl-[2-(O-methyl)tyrosine]arginine-vasopressin, an interesting antagonist of the vasopressor response to vasopressin.
Jones DA; Sawyer WH
J Med Chem; 1980 Jun; 23(6):696-8. PubMed ID: 7392038
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of 8-D-arginine vasopressin analogues, modified in position 1 as antagonists of the vasopressor response to the parent hormone.
Lammek B; Derdowska I; Melin P
Pol J Pharmacol Pharm; 1988; 40(4):423-8. PubMed ID: 3222181
[TBL] [Abstract][Full Text] [Related]
26. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
Manning M; Przybylski J; Grzonka Z; Nawrocka E; Lammek B; Misicka A; Cheng LL; Chan WY; Wo NC; Sawyer WH
J Med Chem; 1992 Oct; 35(21):3895-904. PubMed ID: 1433200
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of arginine vasopressin receptors in the rat testis.
Meidan R; Hsueh AJ
Endocrinology; 1985 Jan; 116(1):416-23. PubMed ID: 2981073
[TBL] [Abstract][Full Text] [Related]
29. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
Varga C; Somlai C; Baláspiri L; László FA
Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
Manning M; Balaspiri L; Moehring J; Haldar J; Sawyer WH
J Med Chem; 1976 Jun; 19(6):842-5. PubMed ID: 950656
[TBL] [Abstract][Full Text] [Related]
31. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
32. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
Manning M; Stoev S; Kolodziejczyk A; Klis WA; Kruszynski M; Misicka A; Olma A; Wo NC; Sawyer WH
J Med Chem; 1990 Nov; 33(11):3079-86. PubMed ID: 2231609
[TBL] [Abstract][Full Text] [Related]
33. Studies of the nature of the interaction between vasopressin and corticotropin-releasing factor on adrenocorticotropin release in the rat.
Rivier C; Rivier J; Mormede P; Vale W
Endocrinology; 1984 Sep; 115(3):882-6. PubMed ID: 6086290
[TBL] [Abstract][Full Text] [Related]
34. Vasopressin-induced antipyresis in the medial amygdaloid nucleus of conscious rats.
Federico P; Veale WL; Pittman QJ
Am J Physiol; 1992 May; 262(5 Pt 2):R901-8. PubMed ID: 1534208
[TBL] [Abstract][Full Text] [Related]
35. Synthesis of arginine-vasopressins, modified in positions 1 and 2, as antagonists of the vasopressor response to the parent hormone.
Lammek B; Rekowski P; Kupryszewski G; Melin P; Ragnarsson U
J Med Chem; 1988 Mar; 31(3):603-6. PubMed ID: 3346876
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and some pharmacologic properties of five novel V1 or V1/V2 antagonists of AVP.
Lammek B; Wang YX; Derdowska I; Franco R; Gavras H
Peptides; 1989; 10(5):1109-12. PubMed ID: 2608555
[TBL] [Abstract][Full Text] [Related]
37. Vascular effects of arginine vasopressin during fluid deprivation in the rat.
Aisenbrey GA; Handelman WA; Arnold P; Manning M; Schrier RW
J Clin Invest; 1981 Apr; 67(4):961-8. PubMed ID: 7204578
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro effects of arginine-vasopressin receptor antagonists on the hypothalamic-pituitary-adrenal axis in the rat.
Bernardini R; Chiarenza A; Kamilaris TC; Renaud N; Lempereur L; Demitrack M; Gold PW; Chrousos GP
Neuroendocrinology; 1994 Nov; 60(5):503-8. PubMed ID: 7845540
[TBL] [Abstract][Full Text] [Related]
39. Biologically active analogues of arginine vasopressin containing conformationally restricted dipeptide fragments.
Lammek B; Czaja M; Derdowska I; Lempicka E; Sikora P; Szkróbka W; Trzeciak HI
J Pept Res; 1998 Feb; 51(2):149-54. PubMed ID: 9516050
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
